Biomanufacturing Industry News
-
Gyros Raises SEK 80M To Accelerate The Commercialization Of Its Gyrolab® Systems For The Cost-Efficient Development Of Biopharmaceuticals
6/30/2009
Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, announces that it has raised SEK 80 million (approximately euro 7.5 million) in an equity fundraising led by SLS Invest, the Company's leading shareholder.
-
Senator Arlen Specter And Richard Gephardt Headline Policy Forum On U.S. Medical Innovation, Highlight Achieving 'Recovery Through Discovery'
6/15/2009
Political leaders and health policy, research and biotechnology experts gathered at a forum today at the Newseum in Washington, D.C., to address the economic impact of policies related to U.S. medical innovation at the "Best & Brightest Forum on Medical Innovation: Achieving Recovery Through Discovery."
-
BioLife Solutions Announces Validation And Start-Up Of New Internal Manufacturing Facility For Serum-Free Cell And Tissue Biopreservation Media Products
6/10/2009
BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading biopreservation tools provider, today announced that it has completed the construction and validation of its internal GMP manufacturing facility and has released the first production lot of its biopreservation media products made in Bothell for commercial sales.
-
Five Cord Blood Transplant Centers In Catalonia And Valencia Join A Study To Test A New Technique To Treat Leukemia And Lymphoma
6/4/2009
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the Excel study.
-
Keryx Biopharmaceuticals Announces Positive Data From A Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study Of KRX-0401 (Perifosine) In The Treatment Of Advanced Metastatic Colon Cancer
6/2/2009
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) yesterday announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer.
-
HHS Awards MedImmune Contract To Manufacture Live Attenuated Nasal Spray Vaccine For Novel Influenza A (H1N1)
6/2/2009
MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1) to vaccinate priority populations identified by HHS in the National Strategy for Pandemic Influenza.
-
FDA Approves Labeling Change For VYVANSE® (lisdexamfetamine Dimesylate) CII To Include Supplementary Clinical Data Supporting Efficacy At 13 Hours Postdose In Children Aged 6 To 12 With ADHD
6/2/2009
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose.
-
Heart Disease Treatment Breakthrough
6/2/2009
A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the killer disease.
-
In Rare Disorder, A Familiar Protein Disrupts Gene Function
5/27/2009
An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromosomes together also plays an important role in regulating genes in humans.
-
Amgen Exercises Option For Exclusive License To Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
5/26/2009
Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program.
This website uses cookies to ensure you get the best experience on our website. Learn more